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1  | INTRODUC TION
Vestibular schwannomas (VSs) are benign, slow‐growing tumours 
originating from Schwann cells of the vestibular part of the eighth 
cranial nerve.1 They represent 6% of all intracranial tumours.2 
Patients with sporadic VS most commonly present between their 
40s and 60s, some with small intracanalicular tumours and others 
with larger extrameatal tumours expanding into the cerebellopon‐
tine angle.3
The possibility to observe tumour development with magnetic 
resonance imaging (MRI) has led to the adoption of a “wait and scan” 
or “monitoring” policy in addition to treatment options; microsurgery 
and stereotactic radiosurgery (SRS).3‐5 Currently, treatment is mainly 
indicated for large and/or growing tumours. Due to monitoring, it is 
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Objectives: To assess the cost‐effectiveness of frequently used monitoring strategies 
for vestibular schwannoma (VS).
Design: A	state	transition	model	was	developed	to	compare	six	monitoring	strategies	
for patients with VS: lifelong annual monitoring; annual monitoring for the first 
10	years	after	diagnosis;	scanning	at	1‐5,	7,	9,	12,	15	years	after	diagnosis	and	subse‐
quently every 5 years; a personalised monitoring strategy for small and large tu‐
mours; scanning at 1, 2 and 5 years after diagnosis and no monitoring. Input data 
were	derived	from	literature	and	expert	opinion.	Quality‐adjusted	life	years	(QALYs)	
and healthcare costs of each strategy were modelled over lifetime. Net monetary 
benefits (NMBs) were calculated to determine which strategy provided most value 
for money. Sensitivity analyses were performed to address uncertainty.
Results: Omitting	 monitoring	 is	 least	 effective	 with	 18.23	 (95%	 CI	 16.84‐19.37)	
QALYs	per	patient,	and	lifelong	annual	monitoring	is	most	effective	with	18.66	(95%	
CI	17.42‐19.65)	QALYs.	Corresponding	 costs	were	€6526	 (95%	CI	5923‐7058)	 and	
€9429	(95%	CI	9197‐9643)	per	patient,	respectively.	Lifelong	annual	monitoring	pro‐
vided	 the	best	value	with	a	NMB	of	€363	765	 (339	040‐383	697),	but	 the	overall	
probability of being most cost‐effective compared to the other strategies was still 
only 23%. Sensitivity analysis shows that there is large uncertainty in the effective‐
ness of all strategies, with largely overlapping 95% confidence intervals for all 
strategies.
Conclusions: Due to the largely overlapping 95% confidence intervals of all monitor‐
ing strategies for VS, it is unclear which monitoring strategy provides most value for 
money at this moment.
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known that approximately two thirds of VSs grow slowly or do not 
grow at all, which resulted in a decline of initial treatment and an 
increase in conservative management.6,7	At	present,	it	is	not	possi‐
ble to predict which VSs pose a threat and which can be safely left 
without intervention; therefore, all patients undergo a monitoring 
strategy with extensive MRI scanning.
Magnetic resonance imaging scans are costly and, with a large 
proportion of patients in a monitoring strategy, contribute signifi‐
cantly to the high costs involved with VS.8 Multiple monitoring 
protocols are used alongside each other, often lacking evidence of 
effectiveness.9,10 Therefore, a cost‐effectiveness model was devel‐
oped to determine the added value of monitoring strategies for VS.
2  | METHODS
2.1 | Ethical considerations
This modelling study was based on published literature and did not 
involve human subjects, and therefore, ethical approval or informed 
consent was not required.
2.2 | Model development
To simulate the follow‐up of patients in a monitoring strategy, we 
developed a state‐transition model in which we simulated costs and 
Keypoints
• The aim was to determine the added value of different 
monitoring strategies for VS.
• The majority of patients with VS are nowadays observed 
through a monitoring strategy. In clinical practice, multi‐
ple monitoring protocols are used alongside each other, 
often lacking evidence of effectiveness.
• Six monitoring strategies were compared: lifelong an‐
nual monitoring; annual monitoring for the first 10 years 
after	diagnosis;	scanning	at	1‐5,	7,	9,	12,	15	years	after	
diagnosis and subsequently every 5 years; a personal‐
ised monitoring strategy for small and large tumours; 
scanning at 1, 2 and 5 years after diagnosis and no moni‐
toring at all.
•	 All	included	monitoring	strategies	had	a	low	probability	
to be most cost‐effective compared to other included 
strategies. Ranging from 23% for lifelong annual moni‐
toring to 11% for no monitoring.
• Due to the largely overlapping 95% confidence intervals 
of all monitoring strategies for VS, it is unclear which 
monitoring strategy provides most value for money at 
this moment.
F I G U R E  1   Influence diagram of the 
Markov model. Patients could enter the 
model via one of the Koos states in the 
monitoring strategy. Koos 1 corresponds 
to an intracanalicular VS, Koos 2 to an 
extracanalicular VS without brainstem 
contact, Koos 3 to VS with brainstem 
contact and Koos 4 corresponds to VS 
that compresses the brainstem. When 
tumour growth was present, patients 
entered the next Koos state. In case 
of Koos state 3 and 4, patients exited 
the monitoring strategy when tumour 
growth	was	detected	on	MRI.	Leaving	the	
monitoring strategy meant transition to 
one of the treatment options; stereotactic 
radiosurgery	(SRS)	or	microsurgery.	After	
treatment, patients were monitored for 
tumour growth. If tumour growth was 
detected after treatment, patients could 
receive additional treatment. The health 
state “dead” is not displayed, but could be 
entered from all health states
Treatment options
Monitoring strategy
Koos 4
Post- 
mircro
surgery
Koos 3 SRS
Micro-
surgery
Post- 
SRS
Koos 2
Koos 1
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quality of life associated with multiple monitoring strategies for VS. 
The target population comprised VS patients who were initially as‐
signed to the monitoring strategy, that is tumours smaller than Koos 
4 at time of diagnosis or small Koos 4 tumours without symptoms 
of brainstem compression (hydrocephalus and symptoms caused by 
cranial nerve failure, eg, swallowing problems).11 The model starts at 
the age of 55, the mean age of diagnosis.12 We assumed every pa‐
tient was eligible for MRI, and loss to follow‐up did not occur. Based 
on clinical guidelines and expert interviews, the model was designed 
in a way that it resembles the clinical situation.
A	 state‐transition	 model	 describes	 the	 conditions	 that	 patients	
can be in (health states), how they can move among such states (tran‐
sitions) and how likely such moves are (transition probabilities). Health 
states in the model were “Koos 1,” “Koos 2,” “Koos 3,” “Koos 4,” “micro‐
surgery,”	“post‐microsurgery,”	“SRS,”	“post‐SRS”	and	“dead”	(Figure	1).	
Patients were assumed to enter the model via one of the Koos states. 
The Koos states represented different tumour sizes in the monitoring 
strategy, for patients who were not treated for their VS. We added 
treatment options to model the consequences of tumour growth. 
Tumour growth was defined as growth to the next Koos state, and in 
case of a Koos 4 tumour as growth to a Koos 4 tumour with brainstem 
compression. Growth within a Koos state and tumour shrinkage were 
not considered growth. Small‐ and medium‐sized tumours (Koos 1 and 
2) which showed growth continued to be monitored without treat‐
ment. Patients received SRS when growth from Koos 2 to 3 was de‐
tected and SRS or microsurgery when growth to Koos 4 was detected. 
We assumed that when a growing VS was not detected and treated in 
time, the patient would visit the hospital with symptoms of brainstem 
compression and would then receive microsurgical treatment. Quality 
of life was lower in the year prior to surgical treatment.
The model had a cycle length of 1 year with a lifelong time hori‐
zon. We applied discount rates to costs and effects, to adjust future 
costs	and	effects	to	present	values.	A	discount	rate	of	4%	was	ap‐
plied	 to	 costs	 and	 1.5%	 to	 quality‐adjusted	 life	 years	 (QALYs),	 ac‐
cording to Dutch guidelines.13
2.3 | Model validation
We	 verified	 the	 model's	 validity	 using	 the	 AdViSHE	 checklist.14 
This checklist covers five aspects of validation: conceptual model, 
input data, computerised model and operational validation and 
other validation techniques. The conceptual model was tested on 
its face validity (the model's appropriateness to represent the clini‐
cal process/disease) by consulting otolaryngology, radiology, SRS 
and neurosurgery experts in the Netherlands. The conceptual model 
was also cross‐validated with other VS models in literature; how‐
ever, no specific health‐economic models for monitoring strategies 
were	found.	Face	validity	of	 the	 input	data	was	tested	by	consult‐
ing the above‐mentioned experts. The computerised model was 
validated by extreme value testing, to detect possible coding errors. 
Operational validity was tested by discussing the model outcomes 
with the above‐mentioned experts. In addition, sensitivity analyses 
were performed to validate the outcomes with alternative input 
data.	Last,	 the	model	was	checked	 for	 inconsistencies	by	an	 inde‐
pendent expert.
2.4 | Strategies
We modelled multiple monitoring strategies for the follow‐up of VS: 
lifelong annual monitoring; annual monitoring for the first 10 years 
after	diagnosis;	scanning	at	1‐5,	7,	9,	12,	15	years	after	diagnosis	and	
subsequently every 5 years; a personalised monitoring strategy for 
small and large tumours; scanning at 1, 2 and 5 years after diagno‐
sis and no monitoring. In the personalised monitoring strategy, small 
tumours (Koos 1 and 2) are monitored 1‐3, and 5 years following 
diagnosis and large tumours (Koos 3 and 4) are monitored 1‐5, 8, 
11	and	16	years	following	diagnosis.	A	strategy	without	monitoring	
was modelled to evaluate the consequences of omitting monitoring, 
since there is discussion about the added value of current monitor‐
ing strategies.9 In the no monitoring strategy, we assumed that if 
symptoms of brainstem compression occurred, patients would visit 
the hospital and undergo microsurgery. We used conservative as‐
sumptions for this strategy: patients acquired brainstem compres‐
sion	when	≥2	mm	growth	in	Koos	4	occurred,	quality	of	life	was	low	
for 1 year when brainstem compression occurred and costs, and 
consequences of microsurgery were adapted to large tumours by as‐
suming a complication rate of 25% instead of 12.5%.15
2.5 | Transition probabilities
Probabilities were derived from literature and expert opinion 
(Table	 1).	 All	 expert‐based	 values	were	 confirmed	 by	 at	 least	 two	
experts. Key inputs were the initial probabilities that divided pa‐
tients over the Koos states, which were derived from Stangerup et 
al,3	that	is	34.7%,	32.2%,	32.2%	and	0.9%	for	Koos	1,	Koos	2,	Koos	
3 and Koos 4, respectively. Transition among Koos states was de‐
fined by the probability of tumour growth to the next Koos state and 
the	probability	to	have	≥2	mm	growth	in	Koos	4.	These	probabilities	
were	derived	from	a	large	(n	=	1217)	retrospective	study	conducted	
in	 our	 hospital	 (Figure	 S1).	 For	 each	Koos	 state,	 follow‐up	was	 at	
least 9 years. Thereafter, we assumed tumour growth not to occur.
2.6 | Costs
The cost analysis was performed from a healthcare perspective, 
meaning all healthcare costs were included. Costs were assessed 
in	 Euros	 (€)	 and	 based	 on	 the	 2017	 price	 level.	 When	 available,	
costs were derived from the Dutch guideline for costing research.13 
Otherwise, unit costs were obtained from hospital fees. Key costs 
were	 consultation	 costs,	 €167	 for	 tertiary	 hospitals	 and	 €82	 for	
general	 hospitals,	 and	MRI	 scans	 of	 €211.	Complication	 costs	 are	
included in the total costs of microsurgery and SRS. To determine 
annual costs after microsurgery or SRS, a scanning protocol with 
scans	at	1‐5,	7,	9,	12,	15	years	after	microsurgery	or	SRS	and	subse‐
quently every 5 years was assumed as this is the current protocol in 
our hospital (Table 1).
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2.7 | Effects
Effectiveness	was	measured	in	QALYs,	which	is	a	combination	of	quality	
of	life	(utility)	and	survival.	A	utility	reflects	quality	of	life	on	a	0‐1	scale,	
with 0 representing death and 1 representing full health. Most quality 
of	 life	values	 for	VS	patients	 in	 literature	are	derived	 from	the	SF‐36	
questionnaire. We used an algorithm to construct a utility value from 
the	domain	scores	of	the	SF‐36	questionnaire	(Table	1).16,17 Quality of 
TA B L E  1   Model parameters
Parameter Valuea  Source
Probabilities
Koos 1 0.347	(α 112, β 211) Stangerup et al3
Koos 2 0.322 (α 104, β 219) Stangerup et al3
Koos 3 0.322 (α 104, β 219) Stangerup et al3
Koos 4 0.009 (α 3, β 320) Stangerup et al3
Dead Standard mortality rates Statistics Netherlands24
Tumour growth to the next Koos state Figure	S1 Patient cohort Radboudumc
SRS after growth in the Koos 3 state 1.00 Expert opinion
Microsurgery after growth in the Koos 4 state 0.900 Expert opinion
Microsurgery complications 0.125 Sughrue et al15
Death as a consequence of microsurgery 0.002 Sughrue et al15
Death as a consequence of SRS 0 Klijn et al25
Growth after microsurgery 0.003 Godefroy et al26
Growth after SRS 0.006 Klijn et al25
Microsurgery in case of growth in the post‐SRS state 0.400 Expert opinion
SRS in case of growth in the post‐microsurgery state 1.00 Expert opinion
Costs
Consultation—tertiary hospital €167 Dutch Guideline for costing research13
Consultation—general hospital €82 Dutch Guideline for costing research13
MRI brain €211 Dutch Guideline for costing research13
Microsurgery—uncomplicated €10	406 Dutch health care administration
Microsurgery—complicated €13	068 Dutch health care administration
SRS €8876 Dutch health care administration
Post‐microsurgery €151	(90%	of	all	patients	are	followed	in	a	
tertiary hospital after microsurgery)
Expert opinion
Post‐SRS €153	(85%	of	all	patients	are	followed	in	a	
general hospital
Expert opinion
Utilities
Monitoring strategy Year	1‐3:	0.831	(SD	0.244) 
Year	4‐6:	0.826	(SD	0.244) 
Year	7‐9:	0.821	(SD	0.244) 
Year	10‐12:	0.816	(SD	0.244) 
Year	13	and	onwards:	0.811	(SD	0.244)
Gait et al19, Godefroy et al18
Symptoms of brainstem compression 0.537	(SD	0.283) Turel et al27
First	year	after	microsurgery 0.688 Gait et al19, Sughrue et al15
First	year	after	SRS 0.789 Gait et al19, Klijn et al25
Post‐microsurgery 0.789 Godefroy et al28
Post‐SRS 0.811 Varughese et al29
Dead 0  
MRI, magnetic resonance imaging; SD, standard deviation; SRS, stereotactic radiosurgery.
aβ‐distributions were assigned to some of the parameters for use in the probabilistic sensitivity analysis. The characteristics of the β‐distribution are 
presented between brackets, either as an SD or as an α and β value (where α represents the number of events in a sample and β the number of 
non‐events). 
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life in the monitoring strategy was assumed to gradually decline, since 
symptoms of asymmetric sensorineural hearing loss, tinnitus and vertigo 
often progress over time.18 In the year of treatment, a lower utility was 
assumed due to potential complications (by calculating the weighted 
mean of treatment associated complications and corresponding utilities).
2.8 | Analysis
A	hypothetical	cohort	of	1000	patients	was	sent	through	the	model	
to	determine	mean	expected	costs	and	effects	(QALYs)	per	patient	
for each strategy. We compared the monitoring strategies to each 
other	by	calculating	the	average	costs	per	QALY.	We	also	calculated	
the net monetary benefit (NMB), which represents the value of a 
strategy in monetary terms. The strategy with the highest NMB rep‐
resents the most cost‐effective strategy. The NMB is calculated by 
multiplying	the	gained	QALYs	by	the	threshold	value	minus	costs	of	
the	monitoring	strategy.	We	used	a	threshold	value	of	€20	000	per	
QALY,	as	recommended	by	the	Dutch	guidelines.13
We performed a scenario analysis in which an alternative treat‐
ment scheme is used. In this scheme, growing Koos 2 tumours which 
were initially diagnosed as Koos 1 were treated with SRS when de‐
tected by MRI. We also performed a probabilistic sensitivity analysis 
with 10 000 simulations to investigate sampling uncertainty concern‐
ing the parameters in the model. We did this for important variables: 
initial probabilities, growth rates, utilities in the monitoring strategy 
and the utility of brainstem compression (Table 1). The percentile 
Strategy Costs (€) Effects (QALYs) NMB (€)
1.	Lifelong	annual	
monitoring
9429	(9197‐9643) 18.66	(17.42‐19.65) 363	765	(339	040‐383	697)
2.	Annual	
monitoring for 
the first 10 y 
after diagnosis
8684	(8297‐9033) 18.54	(17.26‐19.55) 362	174	(336	438‐382	311)
3.	Scans	at	1‐5,	7,	
9, 12, 15 after 
diagnosis and 
subsequently 
every 5 y
8585 (8232‐8911) 18.52	(17.27‐19.54) 361	788	(336	809‐382	335)
4. Personalised 
monitoring 
strategy for 
small and large 
tumours
8149	(7708‐8552) 18.46	(17.15‐19.49) 360 986 (335 032‐381 638)
5. Scans at 1, 2 
and 5 y after 
diagnosis
8032	(7588‐8439) 18.44	(17.12‐19.47) 360	774	(334	483‐381	507)
6. No monitoring 6526	(5923‐7058) 18.23	(16.84‐19.37) 358	168	(330	371‐380	908)
NMB,	net	monetary	benefit;	QALY,	quality‐adjusted	life	year.
TA B L E  2   Outcomes
Strategy
Additional  
costsa  (€)
Additional  
effectsa  (QALYs)
Incremental 
NMBb  (€)
1.	Lifelong	annual	monitoring 199 0.00 −199
2.	Annual	monitoring	for	the	first	10	y	after	
diagnosis
174 0.01 26
3.	Scans	at	1‐5,	7,	9,	12,	15	after	diagnosis	
and subsequently every 5 y
114 0.03 486
4. Personalised monitoring strategy for 
small and large tumours
82 0.03 518
5. Scans at 1, 2 and 5 y after diagnosis 88 0.03 512
6. No monitoring 0 0.00 0
NMB,	net	monetary	benefit;	QALY,	quality‐adjusted	life	year.
In this strategy, growing Koos 2 tumours are treated with SRS when detected. We calculated the 
additional costs and effects for each monitoring strategy, compared to the same monitoring 
strategy in the base case analysis.
aOutcomes of this sensitivity analysis were compared to the base case analysis, for each monitor‐
ing strategy. 
bA	positive	incremental	NMB	indicates	that	the	strategy	is	cost‐effective	compared	to	the	base	
case analysis. 
TA B L E  3  Additional	costs	and	effects	
of using an alternative treatment scheme
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method was used to calculate 95% confidence intervals (CIs) from 
simulations. Simulation results are presented in cost‐effectiveness 
planes	and	cost‐effectiveness	acceptability	curves	(CEACs).	All	anal‐
yses	were	 conducted	using	TreeAge	Pro	2015	 (TreeAge	Software,	
Inc),	and	percentiles	were	calculated	in	Excel	2007	(Microsoft).
3  | RESULTS
We assessed the cost‐effectiveness of multiple monitoring strat‐
egies for the follow‐up of VS. Omitting monitoring is least effec‐
tive	 with	 on	 average	 18.23	 (95%	 CI	 16.84‐19.37)	 QALYs	 while	
lifelong annual monitoring is most effective with 18.66 (95% 
CI	 17.42‐19.65)	 QALYs	 per	 patient.	 Overlapping	 95%	 CIs	 were	
found regarding the effectiveness of all six monitoring strate‐
gies	 (Table	 2).	 Lifelong	 annual	monitoring	was	 the	most	 expen‐
sive	strategy	with	average	costs	of	€9429	(95%	CI	9197‐9643)	per	
patient. Omitting monitoring is the least expensive strategy with 
average	costs	of	€6526	(95%	CI	5923‐7058)	per	patient,	which	are	
mainly treatment costs.
Lifelong	 annual	 monitoring	 had	 the	 highest	 NMB,	 €363	765	
(95%	CI	339	040‐383	697),	 and	 therefore	provides	most	value	 for	
money	 (ie,	 the	 strategy	gained	most	QALYs	at	 a	price	 that	we	are	
willing to pay as society). This strategy was followed by annual 
monitoring	for	the	first	10	years	with	an	NMB	of	€362	174	(95%	CI	
336 438‐382 311). The strategy with the lowest NMB, representing 
the least cost‐effective strategy, was no monitoring with an NMB 
of	€358	168	(95%	CI	330	371‐380	908).	Although	this	strategy	was	
least	 expensive,	 it	 also	 gains	 the	 least	QALYs.	 The	 savings	 in	 this	
strategy	do	not	weigh	up	against	 the	QALYs	 lost,	hence	the	 lower	
NMB of this strategy. The 95% CIs for the NMBs were largely over‐
lapping for all strategies (Table 2).
Using an alternative treatment scheme (in which growing Koos 2 
tumours are treated with SRS when detected) resulted in additional 
costs, as more patients received treatment. Treatment outcomes 
for Koos 2 and Koos 3 tumours were the same, and therefore, no 
differences in quality of life were expected in case of annual mon‐
itoring. However, in other monitoring strategies, treating growing 
Koos 2 tumours resulted in higher quality of life as brainstem com‐
pression is prevented (Table 3). Therefore, alternative treatment is 
F I G U R E  2   Outcomes of the 
probabilistic sensitivity analysis. This 
analysis quantifies the level of confidence 
of	the	model's	conclusions.	All	six	
monitoring strategies are displayed. 
Every dot represents the outcome of one 
analysis
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cost‐effective compared to treating only Koos 3 and 4 in these mon‐
itoring strategies.
In	 Figure	 2,	 the	 incremental	 results	 of	 the	 probabilistic	 sensitiv‐
ity analysis are shown. There is uncertainty in the effectiveness of 
all	strategies,	resulting	in	 largely	overlapping	95%	CIs	for	QALYs	and	
NMBs.	The	CEAC	shows	that	all	strategies	have	a	relatively	low	prob‐
ability to be most cost‐effective due to large uncertainty in the results 
(Figure	3).	At	a	threshold	of	€20	000	per	QALY,	lifelong	annual	mon‐
itoring has a 23% probability to be the most cost‐effective strategy, 
which is higher than annual monitoring for the first 10 years (18%), 
scans	at	1‐5,	7,	9,	12,	15	years	after	diagnosis	and	subsequently	every	
5 years (16%), personalised monitoring (16%), scans at 1, 2 and 5 years 
after diagnosis (15%) and no monitoring (11%).
4  | DISCUSSION
4.1 | Synopsis of key findings
We assessed the cost‐effectiveness of multiple monitoring strate‐
gies for VS. Omitting monitoring is least effective with on average 
18.23	(95%	CI	16.84‐19.37)	QALYs	while	lifelong	annual	monitoring	
is	most	effective	with	18.66	(95%	CI	17.42‐19.65)	QALYs	per	patient.	
Corresponding	 costs	were	 €6526	 (95%	CI	 5923‐7058)	 and	 €9429	
(95%	CI	9197‐9643)	per	patient,	respectively.	Lifelong	annual	moni‐
toring	appeared	to	be	most	cost‐effective	with	a	NMB	of	€363	765	
(95%	 CI	 339	040‐383	697).	 An	 alternative	 treatment	 scheme	 in	
which growing Koos 2 tumours are also treated was cost‐effective 
when patients were not annually monitored. Sensitivity analysis 
shows that there is large uncertainty regarding the effectiveness of 
all strategies.
4.2 | Strengths and limitations
To our knowledge, this is the first study to investigate cost‐effective‐
ness of multiple monitoring strategies of VS. Others have studied 
cost‐effectiveness of treatment strategies such as SRS or microsur‐
gery.19‐21 However, the majority of patients with VS are nowadays 
observed through a monitoring strategy. In clinical practice, multiple 
monitoring strategies are used alongside each other, often lacking 
evidence of (cost‐)effectiveness.9 We therefore studied the cost‐ef‐
fectiveness of different monitoring strategies.
Some	potential	limitations	should	also	be	discussed.	First,	costs	
are based on Dutch healthcare prices and may therefore slightly dif‐
fer from other countries. The same applies to expert opinions, which 
can differ between hospitals and countries. We expect differences 
in exact costs and effects for other countries, but a similar trend. 
Given the detailed presentation of the model and its input parame‐
ters, those interested can assess the transferability of the results to 
their specific situation.
Second, we included VSs of all sizes into the monitoring strategy 
as this represents current practice in the Netherlands. Only 5% of 
tumours receive treatment directly following diagnosis. Monitoring 
for large tumours is more controversial, since the risk of brainstem 
compression is larger. When a less conservative management strat‐
egy is used, relatively smaller tumours will be included in the moni‐
toring strategy with less severe consequences of undetected tumour 
growth. In this case, less intensive monitoring strategies would be‐
come more cost‐effective.
Third,	the	construction	of	QALYs	in	this	model	required	generic	
quality	of	life	scores.	We	used	the	EQ‐5D	or	SF‐36	questionnaires,	
which are relatively insensitive for hearing problems compared to 
disease‐specific	 questionnaires	 such	 as	 the	 PANQOL.	 However,	
there	is	currently	no	algorithm	available	that	converts	PANQOL	out‐
comes	to	generic	utility	scores.	Another	generic	questionnaire,	the	
Health Utilities Index (HUI), does allow for the calculation of utility 
scores. Because it is more sensitive for hearing problems, the HUI 
seems more suitable to measure generic quality of life in patients 
with VS.22 Unfortunately, we were unable to find utility scores mea‐
sured by HUI for use in our model.
Last,	transition	from	one	health	state	to	another	in	the	monitor‐
ing strategy was based on the probability for a tumour to grow to 
the next Koos state. We chose these Koos states since they report 
clearly defined cut‐off points, take tumour size and localisation in 
relation to other structures into account, and have clearly defined 
consequences (ie, recommended treatment).23 We acknowledge 
that by using the Koos states as cut‐off points, we were not able 
to detect growth within a Koos state. However, treatment options 
only change in case of progression to a next Koos state; therefore, 
missing growth within a Koos state does not have consequences for 
treatment.
4.3 | Implications for clinical practice
Currently, large differences in the management of VS are present. 
Multiple monitoring strategies are used alongside each other, with‐
out clear evidence of effectiveness.9 In this analysis, we assessed 
the	cost‐effectiveness	of	several	monitoring	strategies.	Looking	at	
point estimates, lifelong annual monitoring seems most cost‐effec‐
tive. VSs are treated in time in this strategy, preventing serious con‐
sequences of brainstem compression.
However, the 95% CIs are largely overlapping with all other 
strategies. Based on the currently available evidence, the probabil‐
ity that lifelong annual monitoring is cost‐effective is only 23%. This 
implies that if lifelong annual monitoring is implemented, the proba‐
bility	that	this	is	the	wrong	decision	is	77%.	As	there	is	considerable	
uncertainty surrounding this decision, it might be better to wait for 
more evidence before we spend money on extensive monitoring 
strategies.
As	shown	 in	Figures	2	and	3,	 cost‐effectiveness	outcomes	are	
very uncertain with probabilities for a strategy to be most cost‐ef‐
fective ranging from 11% to 23%. The uncertainty is mainly caused 
by uncertain effectiveness outcomes, due to the use of suboptimal 
effectiveness measures in literature and small sample sizes of study 
populations.	 Larger,	 high‐quality	 studies	 that	 investigate	 quality	
of life in VS patients assigned to a monitoring strategy using the 
HUI questionnaire are needed to achieve reliable effectiveness 
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estimates. When research is initiated on this topic, a no monitoring 
strategy should be included. We used conservative assumptions for 
the no monitoring strategy; therefore, we might be underestimating 
the	cost‐effectiveness	of	this	strategy	in	this	paper.	Also,	many	pa‐
tients remain in a monitoring strategy for life without needing treat‐
ment; therefore, a no monitoring strategy could considerably lower 
the costs of monitoring.
In conclusion, due to the largely overlapping 95% CIs of all mon‐
itoring strategies for VS, it is unclear which monitoring strategy pro‐
vides most value for money at this moment.
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